You are here: Industry Insights > NBE-Therapeutics

News List

Boehringer Ingelheim reports positive business growth in 2020 pharmaceutical-technology
March 25, 2021
Boehringer Ingelheim has seen positive business momentum in 2020, according to an annual report published by the biopharmaceutical company on Wednesday.
PPF Group Sells Sake in NBE-Therapeutics to Boehringer Ingelheim americanpharmaceuticalreview
December 31, 2020
PPF Group has announced the signing of a binding agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its proprietary iADC™ platform to develop potential best-in-class antibody-drug conjugate (ADC) ...
Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction contractpharma
December 11, 2020
PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim.
NBE-Therapeutics Begins Anti-ROR1 ADC Study for Solid Tumors americanpharmaceuticalreview
October 30, 2020
NBE-Therapeutics has commenced first-in-human studies of its lead program NBE-002 targeting ROR1, for triple negative breast cancer (TNBC) and other solid tumors.
NBE-Therapeutics Closes USD 22M Series C Financing Round b3cnewswire
January 17, 2020
NBE-Therapeutics AG today announces the closing of a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.
NBE-Therapeutics Appoints Dr. Steffen Heeger as Chief Medical Officer for Leading The Clinical Development of NBE’s iADC Programs b3cnewswire
October 09, 2019
NBE-Therapeutics AG, a biopharmaceutical company developing best-in-class, immune-stimulatory antibody drug conjugates (iADCs™) ...
WuXi Bio, NBE-Therapeutics announce ADC partnership biospectrumasia
April 10, 2019
The partnership with WuXi Biologics will enable the supply of NBE's product for clinical trials under Investigational New Drug (IND) applications worldwide.
Dr. Anthony Tolcher Joins the Scientific Advisory Board of NBE-Therapeutics b3cnewswire
November 17, 2018
NBE Therapeutics AG, a biopharmaceutical company developing next-generation immune-stimulatory antibody-drug conjugates (iADCs™) for improved cancer therapy, today announces the appointment of Dr. Anthony Tolcher to NBE's Scientific Advisory Board (SAB).